Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 August 2018
Prof Coetzee is retelling old stories in a new book
"Failing to Learn Doomed to repeat" was one of the bookworks on display.

The title of Prof Jan K Coetzee’s latest book, Books & Bones & Other Things, says it all. The book looks into the many aspects that have built our society by presenting in a new way the stories contained in old books collected over the years. 

Prof Coetzee is a Senior Professor in the Department of Sociology at the University of the Free State (UFS). Books & Bones & Other Things was launched on 14 August 2018 and coincided with an exhibition of various “bookworks”   art installations by Prof Coetzee that feature old books, sculptures, artefacts, and fossils.
 
Book resulting from research programme 
   

“This is a book on books so the library is the perfect venue to launch a book on old texts as documents of life,” said Prof Coetzee.

For the past seven years he has been directing a Master’s and PhD programme in Sociology called The Narrative Study of Lives. His project, Documents of Life, from which this book came, focuses on a collection of old texts the oldest of which dates back to 1605.

“We live in storytelling societies and for as long as we can remember we have been telling stories. Over time the ability to produce books was born. Any collection of books can tell you a lot about your own life and the society you live in."

“I cannot read the stories of many of these old books because their narratives are closed. I have to re-narrate the books, change the narrative convention and present them in a way that makes sense to me. By combining the books with art and artefacts I want the books to tell their ancient stories in new ways.”

Book launches and intellectual discussions

At the book launch, Prof Corli Witthuhn, Vice-Rector: Research said: “What we have achieved with this launch and exhibition is unbelievable. We always try to create an intellectual space in the library.

“A book such as this is the pinnacle of an academic career. It is multidisciplinary and it looks at the world in a different way. That is what scholarship is about.”

A painting by Robert Hodgins was also handed over to the Johannes Stegmann Gallery, home of the corporate collection of the UFS, at the event. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept